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Mutations in leucine-rich repeat kinase 2 (LRRK2) cause late-onset Parkinson’s disease (PD), but the under-
lying pathophysiological mechanisms and the normal function of this large multidomain protein remain
speculative. To address the role of this protein in vivo, we generated three different LRRK2 mutant mouse
lines. Mice completely lacking the LRRK2 protein (knock-out, KO) showed an early-onset (age 6 weeks)
marked increase in number and size of secondary lysosomes in kidney proximal tubule cells and lamellar
bodies in lung type II cells. Mice expressing a LRRK2 kinase-dead (KD) mutant from the endogenous
locus displayed similar early-onset pathophysiological changes in kidney but not lung. KD mutants had dra-
matically reduced full-length LRRK2 protein levels in the kidney and this genetic effect was mimicked
pharmacologically in wild-type mice treated with a LRRK2-selective kinase inhibitor. Knock-in (KI) mice
expressing the G2019S PD-associated mutation that increases LRRK2 kinase activity showed none of the
LRRK2 protein level and histopathological changes observed in KD and KO mice. The autophagy marker
LC3 remained unchanged but kidney mTOR and TCS2 protein levels decreased in KD and increased in KO
and KI mice. Unexpectedly, KO and KI mice suffered from diastolic hypertension opposed to normal blood
pressure in KD mice. Our ﬁndings demonstrate a role for LRRK2 in kidney and lung physiology and further
show that LRRK2 kinase function affects LRRK2 protein steady-state levels thereby altering putative scaffold/
GTPase activity. These novel aspects of peripheral LRRK2 biology critically impact ongoing attempts to
develop LRRK2 selective kinase inhibitors as therapeutics for PD.
INTRODUCTION
Parkinson’s disease (PD) is the most prevalent neurodegenera-
tive movement disorder with different genetic and environ-
mental etiologies and no existing cure. Clinical motor
features include bradykinesia, rigidity and resting tremor,
but a variety of non-motor symptoms are known, some of
which even precede the appearance of motor symptoms. The
main neuropathological hallmark underlying the clinical
motor features is the loss of dopaminergic (DA) neurons in
the substantia nigra pars compacta. a-synuclein-containing
Lewy structures reminiscent of a speciﬁc proteinopathy are
found in surviving DA but also many other central and periph-
eral neurons including those in the gastrointestinal nervous
∗To whom correspondence should be addressed. Tel: +41 616962388; Fax: +41 616912925; Email: derya.shimshek@novartis.com
# The Author 2011. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Human Molecular Genetics, 2011, Vol. 20, No. 21 4209–4223
doi:10.1093/hmg/ddr348
Advance Access published on August 9, 2011system, and may contribute to the spectrum of non-motor
symptoms in PD patients (1). Human genetics has deﬁned
several mutations in the leucine-rich repeat kinase 2
(LRRK2) gene as a cause of late-onset autosomal dominant
PD that is clinically indistinguishable from idiopathic PD.
LRRK2 mutations account for  5% of familial and 1–2%
of sporadic PD cases and one mutation, G2019S, is most
prevalent (2–7). Although genetics has unequivocally estab-
lished a causal role for LRRK2 mutations in PD, the under-
lying molecular pathophysiology is not understood (8).
Polymorphisms in the LRRK2 gene have also been associated
with disorders including Crohn’s disease (9) and cancer (10).
In vitro, LRRK2 displays kinase activity on itself and artiﬁcial
substrates (11). Physiological substrates have remained
elusive. Nonetheless, the G2019S mutation is located in the
kinase domain and increases LRRK2 kinase activity (12,13)
and toxicity (14–17). Altogether, these ﬁndings provide a ra-
tionale for ﬁnding and developing LRRK2-selective kinase
inhibitors in PD. LRRK2 also has a GTPase as well as a
number of protein–protein interaction domains. Which
domain and function of LRRK2 exerts the protein’s main
up- and/or downstream pathway effector function remains to
be clariﬁed (11). Mouse and human LRRK2 proteins share
86.7% amino acid identity (www.ncbi.nlm.nih.gov/hom
ologene). In the brain, LRRK2 is expressed in the nigrostriatal
pathway as relevant to PD, but is not restricted to this
pathway. In addition, several peripheral organs and cell
types express LRRK2 including kidney, lung and B cells sug-
gesting that LRRK2 mutations may impact physiological pro-
cesses and exert disease-relevant roles outside the nervous
system (9,10). Elucidating the function of the kinase,
GTPase and protein–protein interaction domains of LRRK2,
and investigating its role outside the brain will facilitate a
better understanding of LRRK2-associated PD and promote
the development of LRRK2 bioassays, biomarkers and thera-
peutic strategies. Here we generated LRRK2 mutant mouse
lines to investigate fundamental aspects of LRRK2 biology
in vivo that speciﬁcally relate to its role as a kinase.
RESULTS
Kidney and lung pathology in LRRK2 mutant mice
To determine how kinase function contributes to roles of
LRRK2 in vivo, we generated mutant mice (Supplementary
Material, Fig. S1) carrying either a kinase-inactivating point
mutation D1994S (kinase-dead, KD, Supplementary Material,
Fig. S2) or the kinase-enhancing G2019S pathogenic mutation
(knock-in, KI) that genocopies the human G2019S PD-causing
mutation. Both mutations occur in coding exon 41 of the
murine LRRK2 gene. To distinguish LRRK2 kinase from po-
tential scaffolding functions of LRRK2, we generated mice
lacking LRRK2 completely (knock-out, KO).
In wild-type (WT) mice, the LRRK2 protein is highly
expressed in the kidney (see below and Fig. 5B). Remarkably,
both KO and KD but not KI and WT mice developed dark
kidneys (Fig. 1A–C), thus conﬁrming an earlier report on
KO mice (18) and extending this ﬁnding to KD but not KI
mice even at an age of 26 months. Kidney weight signiﬁcantly
increased in adult homozygous KD males, but remained
unchanged in heterozygous KD males and in 3-month-old
homozygous KD females (Fig. 1A). Histological examination
of KD mouse kidneys at ages between 1.5 and up to 8 months
and from two genetic backgrounds (BALB/c and C57BL/6) all
showed localized microvacuolization manifested as an accu-
mulation of many small isometric vacuoles in epithelial cells
of the proximal tubules in both cortex and outer medulla
(Fig. 1A and data not shown). Starting at the age of 8
months, vacuolated epithelial cells showed in addition a multi-
focal accumulation of granular, yellow–brown autoﬂuorescent
pigment reminiscent of lipofuscin (Supplementary Material,
Fig. S3A) and an indicator for cellular aging (19,20). Like
KD mice, KO mice also showed a male gender-speciﬁc
increase in kidney weight starting around 5 months of age
that persisted life-long but showed no signiﬁcant incremental
increase with age (Fig. 1C and Supplementary Material,
Fig. S3D). Darkening of KO kidneys, however, occurred inde-
pendent of sex starting around the age of 5 months (Fig. 1C). It
did not occur in heterozygous KO mice (data not shown). KO
like KD kidneys started to show diffuse microvesicular vacu-
olation in proximal tubule epithelial cells of the cortex and
outer medulla as early as 6 weeks after birth (Fig. 1C). With
age, microvacuoles became larger and more-and-more
tubules were affected. At age of 5 months, KO like KD
kidneys showed tubular dilatation and increased intracellular
deposition of lipofuscin. In 8-month-old mice, KO but not
KI kidneys showed tubular degeneration and extracellular
deposition of lipofuscin (Fig. 1C and Supplementary Material,
Fig. S3B and C). Interestingly, these LRRK2-speciﬁc patho-
physiological changes in KO kidneys did not prevent or accel-
erate grossly other mouse species-speciﬁc age-related kidney
histopathological changes that are typically observed in WT
(and also KI) mice, such as glomerulonephropathy and tubu-
lointerstitial nephritis (data not shown). We also found no
histopathological evidence of genotype-related cell loss in
kidneys of KO mice (data not shown).
To determine whether the LRRK2-speciﬁc changes impaired
kidney function we performed urinalysis. Twenty-two-month-
oldKOfemales(Fig.1D)and18-month-oldKOmales(Supple-
mentary Material, Fig. S3F) developed proteinuria which was
not yet observed at age 5 months (Fig. 1D) or in 20-month-old
KI males (Supplementary Material, Fig. S3F).
Microvacuolation as a result of LRRK2 ablation was also
seen in lung tissue (Fig. 1E) where LRRK2 is expressed (see
below and Fig. 5B). Here, they were restricted to a subset of
large epithelial cells, classiﬁed as type II pneumocytes, and
located within the alveolar-septal walls. These cells stained
positive for Mucin-1 (data not shown). Type II pneumocytes
are proliferating epithelial cells that produce and secrete
phospholipid surfactant (21,22). Like in the kidney, also in
the lung the changes were apparent already at the age of 1.5
months (Fig. 1E). They did not affect lung weight (Supple-
mentary Material, Fig. S3E). The morphology of the microva-
cuoles in lung cells was similar to those observed in kidney
tubular cells. Neither KD nor KI mice showed similar
changes in the lung (Supplementary Material, Fig. S4 and
data not shown). Other organs in KO mice including the
brain and spleen which both have high levels of LRRK2 in
WT animals (Fig. 5B), and organs such as the heart and
liver showed no LRRK2 genotype-related histopathology
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histopathological ﬁndings demonstrate that LRRK2 serves
homeostatic roles in the kidney and lung and that, when per-
turbed, result in pronounced microvacuolation of select cell
types. Whether these changes are cell autonomously linked
to LRRK2 dysfunction and/or the result of compensatory
mechanisms triggered because of LRRK2-dependent dysfunc-
tion elsewhere in these tissues cannot unequivocally be
demonstrated at this point.
Alterations in proximal tubule secondary lysosomes and
lung type II pneumocyte lamellar bodies
To further characterize the microvacuoles, we ﬁrst performed
immunohistochemistry for lysosome-associated membrane
protein 1 (LAMP1), a marker of late endosomes and
lysosomes. In 6-week-old KO kidneys, tubules showed
increased LAMP1 staining. The LAMP1-positive structures
were enlarged and redistributed from an otherwise apical
localization in WT tubules to a perinuclear distribution in
KO tubules (Fig. 2A). Similar results were obtained in KD
kidneys of 9-month-old mice, analyzed with LAMP2 immuno-
histochemistry (data not shown).
For a more detailed characterization, we performed electron
microscopic (EM) analysis (Fig. 2B). Kidneys of 2-month-old
KO mice revealed an increase in the number and size of sec-
ondary lysosomes in some but not all proximal tubules. At age
6 months, most of the KO kidney proximal tubules contained
enlarged and increased numbers of secondary lysosomes with
typical stacked, whorled membranes, lipid and ﬁne granular
electron dense homogenous material. The fraction of the
whorled membranes was substantially increased in KO when
Figure 1. Kidney and lung pathology in LRRK2 mutant mice. (A–C) Gross appearance, weights of fresh-frozen kidneys and histology of kidney sections stained
with H&E in KD (A), KI (B) and KO mouse kidney (C) or showing autoﬂuorescent material deposited in KO mice (C). Arrows point to microvacuoles (H&E)
and pigment deposits (autoﬂuorescence). Frozen kidney weights (average of left and right kidney): n ¼ 5–16 per group and genotype. (D) Analysis of proteinuria
in female KO and WT mice (5 months old: n ¼ 12 per genotype and 22-month-old mice: n ¼ 5–6 per genotype). Urinary protein content was normalized to
creatinine levels. (E) H&E-stained lung sections from male KO and WT mice. Arrows point to microvacuoles. Age in months (M) and gender are indicated.
Bars in graphs show means and error bars represent SEM. Asterisks indicate signiﬁcance determined by two-tailed t-test, ∗P , 0.05, ∗∗P , 0.01, ∗∗∗P ,
0.001, ns: not signiﬁcant. Scale bars: 25 mm (black), 50 mm (white).
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phospholipid membranes. Further, the number of lysosomes
with lipid and ﬁne granular electron dense material as well
as the number and size of apical vacuoles (phagosomes
which contained cellular debris) was increased. Other cellular
organelles in proximal tubule epithelial cells, such as mito-
chondria and peroxisomes, did not show morphological altera-
tions when compared with the WT. Distal tubules and
glomeruli showed essentially no changes when compared
with WT mice (data not shown).
EM studies on lung tissue from 2- and 6-month-old KO mice
revealed morphological alterations in type II pneumocytes
(Fig. 2C). Lamellar bodies were increased in number and size
showing little or no age-dependent differences. These
lysosome-related organelles store and secrete pulmonary sur-
factant and their lamellae are composed mainly of phospholi-
pids (23). Like in the kidney, no obvious changes were
apparent in other organelles inside type II cells like mitochon-
dria or other lung cell types (data not shown).
These ﬁndings demonstrate that both LRRK2 KO and KD
mutants cause speciﬁc changes in lysosomal homeostasis in
kidney tubule epithelial cells, and the KO mutant also alters
homeostasis of lamellar bodies in lung type II pneumocytes.
Noteworthy, and in contrast to what has been reported (18),
Figure 2. Accumulation of secondary lysosomes in kidney proximal tubule epithelial cells and lamellar bodies in lung type II pneumocytes. (A) Light micros-
copy showing LAMP1 immunostaining (brown DAB staining) in kidney tubules of 1.5-month-old WT and KO mice. Electron microscopy showing kidney cor-
tical proximal (p) and distal (d) tubules (B) and lung alveolar type II cells (C) from 6-month-old WT and 6- or 2-month-old KO mice. Male mice were used for
analysis. (B, upper panel) Normal secondary lysosomes (dashed arrows) and enlarged secondary lysosomes with electron dense material (white arrows) and lipids
(black arrows). V: enlarged apical vacuoles (phagosomes). (B: lower panel) Brush border microvilli (black arrows), normal secondary lysosomes (dashed
arrows), enlarged secondary lysosomes with whorled membranes (white arrows) and lipids (L). V: apical vacuoles (phagosomes), N: cell nucleus. (C) Type
II pneumocyte with normal lamellar bodies in WT lungs (white arrows) and enlarged lamellar bodies in KO lungs (black arrows). Dashed arrows indicate
the surfactant. N: type II pneumocyte cell nuclei, NE: endothelial cell nucleus. Scale bars: 50 mm (A), 20 mm (B, upper panel), 2.5 mm (B, lower panel),
5 mm (C).
4212 Human Molecular Genetics, 2011, Vol. 20, No. 21we found no evidence of a-synuclein accumulation in KO
kidneys (Supplementary Material, Fig. S5).
Blood pressure changes in LRRK2 mutant mice
The kidneys play a central role in salt handling and many genes
thatalterthisprocesscausehypo-orhypertension(24–26).There-
fore,wedeterminedwhetherLRRK2mutationsand/ortheKOand
KD but not KI associated kidney abnormalities inﬂuenced blood
pressure. Telemetric recordings revealed a moderate but signiﬁ-
cant increase in diastolic blood pressure in KO and KI but not in
KD mice (Fig. 3). Notably, we observed no change in vascular
responses of isolated thoraxial and abdominal aorta from KO
and KI mice (data not shown). Heart rate (Fig. 3)a n dw e i g h t
(data not shown) were not affected. Systolic blood pressure was
not altered (Fig. 3). As the KD and KO but not the KI mutants
showed similar histopathological ﬁndings in the kidney, whereas
only KO and KI but not the KD mutants showed changes in
blood pressure, the latter seem to occur independent of the histo-
pathological alterations in the kidney. Furthermore, LRRK2
effects on diastolic blood pressure are likely dependent on
LRRK2 protein expression but not on its kinase function.
Kidney Akt/mTOR/4E-BP1 pathway changes in LRRK2
mutant mice
LRRK2 has been implicated in autophagy (18,27–29), a
process that, when perturbed, could account for an increase
Figure 3. Diastolic hypertension in KO and KI, but not in KD mice. (A–C) Line graphs showing 24 h measurements of the diastolic blood pressure in 1 h
intervals and bar graphs showing the day/night-time mean for diastolic, systolic blood pressure, heart rate and activity for KD (WT: n ¼ 8, KD: n ¼ 9) (A),
KI (WT: n ¼ 7, KI: n ¼ 7) (B), KO (WT: n ¼ 8, KO: n ¼ 8) mice (C). Night-time from 19 to 6 h. Bars in graphs show means and error bars represent
SEM. Asterisks indicate signiﬁcance determined by two-tailed t-test, ∗P , 0.05, ∗∗P , 0.01, ns: not signiﬁcant.
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lung (KO only). However, none of the mutant kidneys showed
alterations in LC3I/II levels (Fig. 4C and Supplementary Ma-
terial, Table S1). Nevertheless, we observed in immunohisto-
chemical analysis an increase of p62 in KO kidneys
(Supplementary Material, Fig. S6) as described before (18)
which seemed to localize to the secondary lysosomes and
thus again implying that lysosomal homeostasis is altered.
We did notice changes in mTOR (mammalian target of rapa-
mycin), a central regulator of autophagy (30) and TSC2 levels;
reduced in KD but increased in KI and KO mutant kidneys
(Fig. 4), but phosphorylation levels of S6(Ser235/236 and
Ser240/244) were not changed suggesting no gross changes
in the activation state of mTOR (Supplementary Material,
Table S1). Akt levels were increased in KD and KO but un-
changed in the KI kidney and the phosphorylation levels of
the PDK1 site (Thr308) were unchanged (Supplementary
Material, Table S1). The levels of 4E-BP1 phosphorylation
were, however, increased in KO (Fig. 4C) and KD (Supple-
mentary Material, Table S1) but not KI mice (Supplementary
Material, Table S1) which suggest reduced suppression of
protein synthesis by 4E-BP1. Note that phosphorylation of
4E-BP1 results in an electrophoretic mobility shift of the
protein to higher molecular weight (31). Similar results were
obtained in KO and KI kidneys with an
anti-phospho-4E-BP1(Thr37/46) antibody (Supplementary
Material, Table S1). Gene expression analysis revealed no
changes in any of the mRNA levels for Akt, mTOR, S6K,
S6 or 4E-BP1 (data not shown) and at the protein level, hetero-
zygous KO mice did not show any alterations (Fig. 4C).
Furthermore, these changes seemed kidney-speciﬁc and were
not observed, for example, in spleen (data not shown). Inter-
estingly, immunoblot analysis also revealed a truncated
mTOR protein in the kidney (Supplementary Material,
Fig. S7; as well as truncated forms of TSC2 and Akt; data
not shown) which levels seemed inversely correlated with
those of the full-length mTOR protein in KD and KO but
not KI mice (Supplementary Material, Fig. S7). Unlike these
changes in older kidneys, 6-week-old kidneys, which appeared
grossly normal but already manifested microvacuoles,
revealed no changes in the levels of mTOR, Akt or TSC2
(data not shown). Therefore, most of these changes are
likely secondary and compensatory.
LRRK2 kinase function is essential for LRRK2
protein stability
Full-length LRRK2 protein levels were similar in organs,
including the brain, kidney, lung and spleen (Fig. 5A and
B). Different brain regions, like striatum, hippocampus,
cortex and cerebellum, expressed similar amounts of the
LRRK2 protein, while others (e.g. brainstem) had much
lower levels (data not shown). In the kidney, a prominent trun-
cated form of LRRK2 (t1) was detected which was absent in
KO (Fig. 5B), reduced to  50% in heterozygous KO
(Fig. 5C), unchanged in KI mice (Fig. 5D) and present only
in much smaller amounts in other organs (Fig. 5B). Notably,
homogenization conditions (degree of blockade of phospha-
tases/proteases) determined the extent and pattern of proteolyt-
ic cleavage of LRRK2 (Supplementary Material, Fig. S8), thus
Figure 4. Alterations in Akt/mTOR/4E-BP1 levels in the LRRK2 mutant kidney. (A–C) Immunoblot quantiﬁcations of total kidney lysates (in % normalized to
WT) and representative examples thereof from KD (WT, KD: n ¼ 6–7) (A), KI (WT, KI: n ¼ 9–10) (B) and KO (KO (Ho), heterozygous KO (He) and WT: n ¼
6–8) mice (C). a4E-BP1 represents non- or single-phosphorylated and b4E-BP1 double-phosphorylated 4E-BP1 (C). Asterisks indicate signiﬁcance determined
by two-tailed t-test: ∗P , 0.05, ∗∗P , 0.01, ∗∗∗P , 0.001, ns: not signiﬁcant. Individual mice are shown as circles, the means are indicated as lines. The age in
months (M) and gender of the mice are indicated. b-Actin was used as loading control and for Akt and 4E-BP1 normalization.
4214 Human Molecular Genetics, 2011, Vol. 20, No. 21highlighting the importance of well-controlled conditions in
biochemical experiments regarding LRRK2. To eliminate or
minimize artifacts during sample preparation, we inhibited
proteases and phosphatases as described under ‘additional
phosphatase and protease inhibitors’ in the Material and
Methods section. t1 represents a truncated form of LRRK2
that includes the leucine-rich repeat (LRR) region and the
kinase domain as shown by mass spectrometry analysis of
pull-down material with LRRK2-inhibitor coated beads (data
not shown). In KD mutants, the levels of full-length LRRK2
in the kidney (Fig. 5A and E) and brain (Supplementary Ma-
terial, Fig. S9A) (less in the lung or spleen) were dramatically
reduced, while t1 in kidney remained unchanged (Fig. 5E).
The spleen contained nearly similar levels of full-length
LRRK2 (Fig. 5A) and pull-down experiments using
LRRK2-inhibitor coated beads on kidney or brain samples
conﬁrmed that active-site ligand binding was retained in the
D1994S KD mutant (data not shown). This suggests that im-
proper folding and/or conformational instability of the
LRRK2-D1994S full-length protein is an unlikely explanation
for its decreased levels in the kidney. The lack of higher levels
of KD protein in the insoluble fraction of the homogenized
kidney further suggests that this mutant does not have a
greatly increased propensity to aggregate (Supplementary Ma-
terial, Fig. S9B). This view is further supported by our ﬁnding
that pharmacological inhibition of LRRK2 using a low mo-
lecular weight adenosine triphosphate (ATP)-competitive
kinase inhibitor (Supplementary Material, Table S2) reduced
the level of full-length LRRK2 in the kidney of both WT
(Fig. 5F and Supplementary Material, Fig. S10A, a second in-
dependent study in WT animals) and, slightly less, also in KI
mouse kidney (Supplementary Material, Fig. S10B).
These ﬁndings demonstrate the existence of a truncated form
of LRRK2 that is present mainly in the kidney. Further, they il-
lustrate that LRRK2 kinase function is needed for the homeo-
stasis of the full-length LRRK2 protein in the kidney.
No overt neuropathology and normal locomotor responses
to dopamine agonists/antagonists in KO and KI mice
Unlike the histopathological changes in the kidney and lung,
histo- and immunohistochemical evaluation of LRRK2
mutant brain tissue failed to reveal LRRK2-dependent qualita-
tive or quantitative changes. We probed markers for DA
neurons [tyrosine hydroxylase (TH), dopamine transporter
(DAT)], striatal GABAergic projection neurons [dopamine-
and cAMP-regulated neuronal phosphoprotein (DARPP-32)],
neuroﬁlament (SMI), a-synuclein (aSN), astrocytes [glial
ﬁbrillary acidic protein (GFAP)] and microglia [ionized
calcium binding adaptor molecule 1 (Iba1)] and all showed
distribution patterns and staining intensities similar to WT
littermates (Supplementary Material, Fig. S11; data not
shown). Striatal dopamine levels and its metabolites
dihydroxyphenyl-acetic acid and homovanillic acid were
also unchanged in KO and KI when compared with WT
mice (data not shown). Also functional changes in the nigro-
striatal system were not detected when probing locomotor
responses of KO (Supplementary Material, Figs S12 and
S13) and KI (Supplementary Material, Fig. S12) to dopamine
D1 and D2 receptor agonists and antagonists (see ﬁgures for
details). LRRK2 mutations therefore do not result in obvious
structural or selected drug-evoked behavioral changes in the
nigrostriatal pathway.
DISCUSSION
Here we described several novel aspects of peripheral LRRK2
biology that emerged by studying LRRK2 function in three
Figure 5. LRRK2 kinase function required for stability of full-length LRRK2
protein. (A–F) Immunoblots detecting LRRK2 protein in different tissues of
adult KD (A) and KO (B) and in the kidney of adult heterozygous KO (het/
hetKO) (C), KI (D), KD (E) and kinase inhibitor-treated mice (F). Besides
LRRK2 full-length (ﬂ), truncated LRRK2 species were observed mainly in
the kidney (most prominent band is indicated as t1). The approximate molecu-
lar weight of LRRK2 ﬂ and t1 is indicated. (C–F) Immunoblot quantiﬁcations
of extracts of total kidney from heterozygous KO (WT, hetKO: n ¼ 6–7) (C),
KI (WT, KI: n ¼ 5–6) (D), KD (WT, KD: n ¼ 6) (E) and mice treated with
the LRRK2 kinase inhibitor (vehicle, Veh; inhibitor, Inh: n ¼ 6–7; 30 mg/
kg, p.o., twice daily, 5 days, killed 2 h after last dosing) (F). Shown are quan-
tiﬁcations of ﬂ and t1 (in % normalized to WT and vehicle, respectively). In-
dividual mice are shown as circles, means are indicated as lines. Asterisks
indicate signiﬁcance determined by two-tailed t-test: ∗∗P , 0.01, ∗∗∗P ,
0.001. b-Actin was used as loading control.
Human Molecular Genetics, 2011, Vol. 20, No. 21 4215different LRRK2 mutant mouse lines. These ﬁndings bear on
ongoing attempts in various laboratories, to develop LRRK2
selective kinase inhibitors as therapeutics for PD.
LRRK2 plays a role in mouse kidney and lung homeostasis
Our histopathological ﬁndings in KO mice reveal an important
physiological role of LRRK2 in the mouse kidney and conﬁrm
initial observations made in a different line of LRRK2 KO
mice (18); LRRK2 deletion leads to kidney darkening and
lipofuscin accumulation. Here we demonstrate that these
changes manifest already at the age of 5 months, much
earlier than reported previously at 20 months of age when
both kidney size and weight were found to be reduced (18).
In contrast, we found a male gender-speciﬁc increase in KO
kidney weight starting at the age of 5 months. Note we also
observed increased genotype-independent kidney weight in
males. Hence, it is important to consider the gender in the ana-
lysis. Irrespective, discrepancies between our ﬁndings and the
previous study may be due to differences in strain background
of the mutant mice (ours BALB/c and C57BL/6 versus B6:129
in the previous study). Kidney hypertrophy in KO males might
be the result of an increase in protein translation, for example,
in response to renal injury as the mice age (32) and/or a de-
crease in protein degradation (33). In fact, our data suggest
that both processes might play a role. We found signiﬁcantly
increased levels of phosphorylated 4E-BP1 reminiscent of
reduced 4E-BP1-mediated suppression of protein translational
initiation. In addition, we noted an age-dependent accumula-
tion of lipofuscin suggesting impaired proteolysis.
Our ﬁndings suggest that the complete absence of the
LRRK2 protein or expression of a KD, but not its enhanced
(G2019S) kinase variant as has been reported (34), increases
4E-BP1 phosphorylation levels in the kidney, thereby likely
regulate protein translation in a LRRK2-dependent fashion
(34,35). Higher 4E-BP1 phosphorylation could also be the
result of stress-induced protein kinases (13) that might have
been activated in KO and KD kidneys. It remains puzzling,
however, why kidneys enlarge only in KO males but not in
females. In any case, we did not observe kidney abnormalities
in heterozygous LRRK2 KO mice that express  50% less
LRRK2 protein when compared with WT mice. Therefore, it
appears that the kidney changes occur only after complete
loss or a substantial decrease in LRRK2 protein levels as it
is the case in the KD kidney (see below).
As early as 6 weeks after birth, a time point that precedes
the darkening of the kidneys and the deposition of lipofuscin,
we observed abnormal microvacuolization in KO kidney prox-
imal tubule cells, a phenomenon that has not yet been
described. Likewise, in KO lungs, type II pneumocytes devel-
oped microvacuoles at age 6 weeks. These new ﬁndings
suggest that LRRK2 plays an important role in both the
mouse kidney and lung. Ultrastructural (EM) characterization
of adult KO organs clearly showed that the microvacuoles rep-
resent secondary lysosomes in renal proximal tubules and la-
mellar bodies in lung alveolar type II cells. Lamellar bodies
are lysosome-related organelles referred to as secretory lyso-
somes (23). They store and secrete proteins and surfactant
phospholipids (organized into tightly packed, bilayer mem-
branes) which reduce surface tension in the alveoli and
prevent alveolar collapse during expiration. Further, they
contain characteristic lysosomal enzymes (acid phosphatases
and cathepsins) and membrane proteins (CD63 and LAMP1)
(36–38). Perhaps interesting, we had noted that KO mice
manifested breathing difﬁculties under deep isoﬂurane anes-
thesia when we implanted the telemetric devices. How the
observed abnormalities in lamellar bodies inﬂuence surfactant
and lung function needs to be addressed in future studies. In
any case, the increased numbers of microvacuoles in both
renal proximal tubules and lung alveolar type II cells of KO
mice seem to reﬂect very similar LRRK2-dependent and/or
compensatory endosomal–lysosomal pathway changes in
both tissues. In the brain, we did not observe similar
changes and LRRK2 function in this organ still remains to
be elucidated.
LRRK2 protein scaffold versus kinase-domain function
KO mice completely lack the LRRK2 protein. Therefore,
phenotypic changes observed in these mutant mice cannot
be assigned to the protein’s role in scaffolding versus roles
exerted by its kinase and/or GTPase domain. To this end,
we generated KD mutant mice which developed early-onset
(6 weeks after birth) microvacuolation in kidney like KO
mice but failed to show a KO-like phenotype in the lung.
Most striking were the notably reduced levels of full-length
LRRK2 protein levels in the KD kidney (see below for discus-
sion). These levels were even substantially lower than those in
the heterozygous KO kidney. In the lung, full-length LRRK2
protein levels were slightly reduced but by far not as marked
as in the kidney. These ﬁndings imply that the loss of
LRRK2 kinase function in the kidney results in a signiﬁcant
reduction in full-length LRRK2 protein levels. Hence, it is dif-
ﬁcult to assign a loss-of-function-related phenotype in the KD
mutants to the kinase domain. Irrespective, our ﬁndings dem-
onstrate that LRRK2 kinase inactivation triggers changes in
the kidney that may or may not be desirable.
Interestingly, although similar changes in the kidney oc-
curred in KD and KO mice, only KO mice showed changes in
blood pressure. Therefore, it seems highly unlikely that these
two changes are causally linked. This is further supported by
our ﬁndings that also the G2019S KI mutant mice had an in-
crease in diastolic pressure, while these animals showed none
of the histopathological kidney changes observed in KO and
KD mice. Note, PD patients, including LRRK2 patients, can
manifest neurocirculatory abnormalities, including disturbed
baroreﬂexes and/or supine hypertension (39).
So far, none of the histopathological changes observed in the
periphery has shown counterparts in the brain and also
drug-evokedbehavioralresponsesdesignedtopick-uppotential
LRRK2-dependent changes in the nigro-striatal pathway have
also largely not met with success. Further studies are needed
to elucidate the role of LRRK2 in the nigro-striatal system.
Cell autonomous or non-autonomous role for LRRK2 in
altered lysosome homeostasis
We demonstrated an abnormal increase in both number and
size of secondary lysosomes in proximal tubule cells of KO
and KD kidneys, suggesting a speciﬁc role of LRRK2 in
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seems supported also by the ﬁnding that lipofuscin accumu-
lates. Lipofuscin consists largely of highly oxidized and cross-
linked proteins and lipids that are no longer properly degraded
by lysosomes or the proteasomal system. Intracellular accumu-
lation of lipofuscin is a feature of postmitotic aging (40). In
adult mouse kidney, LRRK2 mRNA is highly expressed in
podocytes and lower in the proximal tubule (41). This could
suggest that the abnormal increase in the number of secondary
lysosomes in proximal tubule cells is the result of a
cell-autonomous LRRK2 defect. Alternatively, this phenotype
in proximal tubule cells is a compensatory change in the
kidney that might occur secondary to LRRK2-dependent
physiological changes elsewhere in the kidney, podocytes
being one suspect. We did notice proteinuria in old but not
young KO mice that could point to defects in lysosomal func-
tion. In the kidney, proteins are ﬁltered in the glomeruli and
reabsorbed in the proximal tubule through receptor-mediated
endocytosis before being transferred to lysosomes for proteo-
lytic degradation (42). Proteinuria occurs if either glomerular
ﬁltration (glomerular proteinuria) or tubular reabsorption of
proteins is impaired (tubular proteinuria). The histological
changes we observed in proximal tubule cells of KO kidneys
and the absence of overt genotype-related changes in glom-
eruli seem to favor the hypothesis that the proteinuria we
observed in old KO mice is due to reduced tubular rather
than glomerular function. However, further analyses need to
unequivocally discriminate between these possibilities.
The LRRK2 protein has been suggested to localize to the
endosomal–lysosomal compartment and pathogenic LRRK2
mutations have been proposed to perturb endosomal–lyso-
somal trafﬁcking (27,28,43–46). Lysosomal dysfunctions in
PD seem frequent. This is exempliﬁed by defective lysosomal
glucocerebrosidase function in Gaucher patients where PD
risk is highly increased (47,48).
LRRK2 has also been implicated in autophagy (18,27–29).
But we did not ﬁnd alterations in the autophagy marker LC3I/
II indicative of either an increase or decrease in autophagy
despite an accumulation of a second autophagy marker p62
(49) presumably in secondary lysosomes. p62 is sequestered
to autophagosomes and then degraded after fusion with lyso-
somes (49). Taken together, the data indicate that lysosomal
homeostasis is perturbed rather than autophagy itself. Never-
theless, we observed LRRK2 kinase-dependent changes in
the kidney mTOR pathway, which is important in controlling
autophagy (30). While in the KD kidney TSC2 and mTOR
protein levels were decreased, they were increased in KI
kidney and, interestingly, also in the KO kidney. The mTOR
pathway changes seemed to be organ speciﬁc as no change
could be observed in the spleen. In addition, they are presum-
ably also independent of kidney pathology as the KD mice,
despite similar pathological changes as in KO mice, displayed
the opposite effect compared with KO and KI mice, the latter
showing no signs of pathology. The observed prominent lower
molecular weight protein of mTOR in the kidney may again be
pathology independent and is likely to be mTORb (50), a trun-
cated kinase-active form of mTOR, that perhaps is still
capable of phosphorylating 4E-BP1. Truncated forms could
be detected for TSC2 and Akt; however, little is known
about these forms, opening up speculations of LRRK2
kinase activity involvement in modulating protease activity.
Whether the biochemical mTOR-pathway alterations seen in
KI and KO mice are causally linked to the directionally
similar changes in blood pressure in these mutants remains
to be established (51).
Intact LRRK2 kinase function is essential for homeostasis
of LRRK2 protein
The levels of the LRRK2 full-length protein were reduced
markedly in the KD kidney, whereas other organs showed
some (brain . lung) or almost no such effect (spleen).
Pharmacological inhibition of LRRK2 kinase in WT and KI
mice also reduced LRRK2 full-length protein levels in the
kidney. Therefore, a kidney-speciﬁc destabilization of the
LRRK2-D1994S KD mutant resulting in decreased full-length
protein levels seems an unlikely explanation for its decreased
levels in the kidney. Rather, these ﬁndings demonstrate that
the LRRK2 kinase function is essential for maintaining
normal LRRK2 full-length steady-state protein levels. Some-
thing similar could not be observed in vitro in different cell
lines overexpressing LRRK2 mutants and treatment with
kinase inhibitors (data not shown). Interestingly, a similar
mechanism regulating Rip2 levels has been proposed (52).
Rip2 has a kinase domain that is closely related to the
kinase domain in LRRK2 (53). Although the underlying mo-
lecular mechanism remains speculative, it is known that
pharmacological inhibition of LRRK2 kinase results in depho-
sphorylation of its Ser910/Ser935 residues [probably via inhib-
ition of a protein kinase, e.g. PKA that can phosphorylate
Ser935 (54) or activation of a protein phosphatase], disruption
of 14-3-3 protein binding and altered localization of LRRK2 in
the cytoplasm (55,56). However, it was not reported whether
kinase inhibitors also change LRRK2 protein levels and
future experiments should elucidate the precise molecular
mechanism responsible for kinase inhibitor-mediated destabil-
ization of the full-length WT and mutant protein.
We speculate that a decrease in LRRK2 levels, as shown in
the KD mutant and following pharmacological inhibition, may
also bear on the PD-relevant pathomechanism caused by
certain LRRK2 mutants, such as I2020T. This pathogenic fa-
milial PD LRRK2 mutation (57) affects an amino acid next
to glycine 2019, and was shown to decrease LRRK2 autopho-
sphorylation, the phosphorylation of its putative substrates
moesin and myelin basic protein (58) and the artiﬁcial sub-
strate LRRKtide (59). Conﬂicting data aside on whether the
I2020T mutation affects kinase activity per se (60), it was
shown that the LRRK2 I2020T protein is more susceptible
to post-translational degradation when compared with WT or
the G2019S mutant (60). Nonetheless, the value of these ﬁnd-
ings will become apparent if they translate, for example, to
human I2020T patient ﬁbroblasts. Following the same line
of thought, it is more difﬁcult to explain the pathogenic
effects of the G2019S mutation which enhances kinase activity
and did not show any destabilization effects on the protein in
the kidney of mutant mice. We can only speculate. But the
ﬁnding that physiological changes in blood pressure show
the same direction in KO and G2019S mutants could
suggest that the net output of LRRK2 signaling by the
G2019S mutant and the full KO might be similar.
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to early-onset histopathological abnormalities in the kidney
(microvacuoles, lipofuscin deposits) indistinguishable from
those observed in mice lacking LRRK2. KO but not KD
mice develop a similar pathology in lung, suggesting that a
LRRK2 scaffold and/or GTPase rather than its kinase function
is causally linked to abnormalities in the lung. Diastolic blood
pressure changes in both KI and KO but not KD mice seem to
suggest that these physiological changes are LRRK2 kinase
function independent and the fact that they occur in G2019S
mutants demonstrates that they are independent of kidney
histopathological changes seen in KO and KD mutants.
Finally, LRRK2 kinase function determines the stability of
the full-length LRRK2 protein and kinase inhibition lowers
LRRK2 protein levels. Appreciating the molecular complexity
of LRRK2 signaling and phenotypic changes calls for a cau-
tious evaluation of LRRK2-directed therapeutics.
MATERIALS AND METHODS
Statement on animal health
All experiments were carried out in accordance with the
authorization guidelines of the Swiss federal and cantonal vet-
erinary ofﬁces for the care and use of laboratory animals.
Studies described in this report were approved by the Swiss
cantonal veterinary ofﬁce and performed according to Novar-
tis animal license numbers 2063, 2382 and 95.
Generation of LRRK2 gene-modiﬁed mice
Cloning of the LRRK2-G2019S targeting vector. LRRK2
genomic sequences containing exon 41 were ampliﬁed from
Balb/c mouse genomic DNA and subcloned. Site-directed mu-
tagenesis was performed to modify codon GGG (Gly) to TCG
(Ser), resulting in the desired G2019S mutation in exon 41. A
loxP element was inserted into a BglI restriction site 5′ of exon
41. Modiﬁed genomic sequences were excised by HindIII and
subcloned into the HindIII restriction site of pRAY2 (Acces-
sion No. U63120). LRRK2 genomic sequences downstream
of exon 41 were ampliﬁed as described above and subcloned
using ClaI/NotI into pRAY2 containing the cloned modiﬁed
exon, resulting in the LRRK2 target plasmid.
Cloning of the LRRK2-D1994S targeting vector. LRRK2
genomic sequences ﬂanking exon 41 were ampliﬁed from
Balb/c mouse genomic DNA and subcloned. Overlapping
polymerase chain reaction (PCR) was performed to modify
codon GAC (Asp) to TCC (Ser), resulting in the desired
D1994S mutation in exon 41. Modiﬁed genomic sequences
were subcloned into the HpaI/XhoI-digested vector
pRAY2-LRRK2 5′ arm. LRRK2 genomic sequences down-
stream of exon 41 were ampliﬁed as described above and sub-
cloned using ClaI/NotI into pRAY2 containing the cloned
modiﬁed exon, resulting in the plasmid LRRK2-D1994S
target. Subcloned sequences were compared with sequences
available from the Ensembl database (Ensembl Gene ID
ENSMUSG00000036273).
Transfection of mouse embryonic stem cells. Embryonic stem
(ES) cells were cultured in 6 cm dishes containing primary
X-ray-inactivated embryonic ﬁbroblast cells from DR4 mice
(TgN(DR4)1Jae (61). ES cells were transfected by electropor-
ation of 20 mgo fNotI-digested pLRRK2 target plasmid. Trans-
fected ES cells were selected for neomycin resistance with
0.2 mg/ml geneticin (G418, Invitrogen #10131-019). Ten days
after transfection, G418-resistant ES cell clones were isolated
and analyzed by PCR (nested PCR: ﬁrst PCR: sense primer:
Neo-4: TCC TCG TGC TTT ACG GTA; antisense primer:
LRRK2-rev1: CCC GTC AGT AAG TGA GCT; second
PCR: sense primer: Neo-5: CTA TCG CCT TCT TGA CGA
A; antisense primer: LRRK2-rev2: CTT TGA CCT TGG
GAT GAA) for homologous recombination. An additional
PCR was performed to control for the presence of the loxP
element 5′ of LRRK2 exon 41 (sense primer: LRRK2-geno.for:
GTG TTA AAG CTC CAG TTG CCT; antisense primer:
LRRK2-geno.rev: GCC AGA GAG TAC ACA GGA GGT).
To eliminate the ﬂp recombinase recognition site
(FRT)-ﬂanked neomycin cassette in ES cells, cells were
co-transfected with the plasmids pEGFP-N1 (Accession No.
U55762) and pCAG-FLP at a ratio of 1:4 using
LipofectamineTM 2000 (Invitrogen #11668-027) as transfec-
tion reagent. Two days after transfection, enhanced green
ﬂuorescent protein-expressing ES cells were collected by
ﬂuorescence-activated cell sorting (FACS) (FACSCalibur,
Becton Dickinson) and cultured for a further 6 days in
normal media. Forty-eight single clone cells were selected
and split onto two plates. Cell culture was performed on a
96-well plate with feeder (0.5 × 10
6 inactivated feeder cells/
96-well plate) in the ES medium with or without G418
(0.2 mg/ml G418). PCR to control for Flp-mediated FRT re-
combination and excision of the neomycin cassette were per-
formed (sense primer: LRRK2-geno.for: GTG TTA AAG
CTC CAG TTG CCT; antisense primer: FRT(-neo)rev: TTT
CGA ACC CGG GGA AGT TC).
Southern blot analysis. Homologous recombination of the tar-
geting plasmid into the LRRK2 locus was veriﬁed by southern
hybridization. For this purpose, genomic DNA from ES cell
colonies was digested with the restriction enzyme EcoRV,
blotted and hybridized with a labeled neomycin probe. In
brief, 5 mg of genomic DNA were digested with 30 units of
the restriction enzyme and separated on a 0.9% agarose gel.
After denaturation, the DNA was blotted on a Hybond N+
membrane (Amersham #RPN203B) followed by UV crosslink-
ing. Hybridization with the
32P-labeled DNA probe (Rediprime
II Random prime labeling kit, Amersham #RPN1633) was per-
formed in Perfect Plus Hybridization buffer (Sigma #H7033) at
658C overnight. After washing of the hybridized membrane,
image analysis was performed using a phosphoimager.
Blastocyst injection and generation of gene-modiﬁed animals.
Targeted Balb/c ES cells were injected into C57Bl/6J host
blastocysts, which were then transferred into pseudopregnant
B6CF1 foster mothers. Chimeric offspring were identiﬁed by
coat pigmentation [white (Balb/c) on a black (C57Bl/6J) back-
ground]. White offspring indicated the germline transmission
of the targeted ES cells and were further analyzed for their
correct genotype.
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LRRK2 G2019S KI males with either BALB/c or C57Bl/6J
Cre-deleter females (B6-TgN(CMV-Cre)#Cgn (62) that
express the Cre recombinase in the fertilized oocyte, resulting
in deletion of the ﬂoxed fragment in all cells of the organism
(KO). Offsprings of the crossing were analyzed by PCR to
identify mice in which Cre recombination has taken place.
Cre recombination should take place in offspring containing
both the targeted LRRK2 allele as well as the gene for Cre re-
combinase. This event should result in a PCR product of
150 bp instead of 816 bp from the non-recombined allele
(sense primer: LRRK2-geno.for: GTG TTA AAG CTC CAG
TTG CCT; antisense primer: FRT(-neo)rev: TTT CGA ACC
CGG GGA AGT TC).
Mice were kept either in BALB/c background or were back-
crossed into C57Bl/6J. For backcrossing of LRRK2 KO and
KI lines into C57Bl/6J we applied speed congenics. For the
experiments, we used mice that were backcrossed either at
least six generations or at least two generations (LRRK2 KD
and aged LRRK2 KI) into C57Bl/6J.
Non-transgenic control mice were either littermates (from a
heterozygous breeding) or from a WT breeding of the respect-
ive line from the same generation to reduce animal numbers.
Genotyping
Gene-modiﬁed mice were selected by standard Taqman PCR
analysis of tail DNA with primers and ﬂuorescently labeled
probes: KD: LRRK2-2lox.for TA (5′-CGA AAA CAG CAA
CAA CGA CAA C-3′), LRRK2-2lox.rev TA (5′-ATA GGA
ACT TCT TGG CTG GAC-3′), LRRK2.KD-probe
(5′-FAM-TCC GAG CCA AAA ACT CTC GAG GAA
TT-TAMRA-3′); KI: LRRK2-2lox.for TA (5′-CGA AAA
CAG CAA CAA CGA CAA C-3′), LRRK2-2lox.rev TA
(5′-ATA GGA ACT TCT TGG CTG GAC-3′),
LRRK2.2lox-probe (5′-FAM-TCC GAG CCA AAA ACT
AAG CTT CTC GA-TAMRA-3′); KO: LRRK2.for (5′-TGT
ATC CCA ATG CTG CCA TC-3′), LRRK2.rev (5′-CTA
TAT CTC CTA GAC CCA CAC-3′), LRRK2.Ex41.probe
(5′-YYE-TGG GAA TAA AGA CAT CAG AGG GCA
C-TAMRA-3′). As endogenous control PCR: aSN-5′
(5′-GCT GGA AAG ACA AAA GAG GG-3′), aSN-3′
(5′-ATT CTC TCA CCT CCA CAC AG-3′), aSN-probe
(5′-FAM or YYE-TGG CTG GTG TGT GGT GTC TGA
TT-TAMRA-3′). Rotorgene 3000 was used for PCR (at 958C
for 10 min, 40 cycles at 958C for 15 s and at 608C for 1 min).
Immunoblot analysis
For near-infrared Li-cor western blot analysis, kidneys and
brains were homogenized in homogenization buffer (10v/w)
(additional phosphatase and protease inhibitors: 50 mM Tris–
HCl, pH 7.4; 150 mM NaCl; 1.5 mM MgCl2; 5% glycerol;
1m M Na3VO4;2 5m M NaF; 1 mM dithiothreitol (DTT); 0.8%
NP-40 (add NaF, DTT and NP-40 just before use), complete
ethylenediaminetetraacetic acid (EDTA)-free protease
inhibitors (Roche), 0.5 mM PMSF (Sigma), 5 mg/ml Pepstatin
A (Sigma), 5 mg/ml Leupeptin (Sigma), 1:1000 Okadaic
acid 100 ng/ml in ethanol (Biomol), 1:1000 Calyculin A
100 ng/ml in ethanol (Biosource), 1:100 Pierce phosphatase
inhibitor cocktail ×100 with Precellys24 (Bertin Technolo-
gies, rotation speed 5000 rpm, number of cycles: brain—2 ×
30 s, pause: 10 s; kidney—2 × 50 s, Pause: 10 s), then incu-
bated for 30 min on ice and subsequently centrifuged at
13K rpm at 48C for 10 min.
Homogenization buffer containing only standard phosphat-
ase and protease inhibitors: 10 v/w; 0.25 M sucrose, 20 mM
Tris 20 mM pH 7.4, 1 mM EDTA, 1 mM EGTA, protease in-
hibitor cocktail (Roche).
Homogenization buffer containing additional phosphatase
and but only standard protease inhibitors: 10 v/w; 0.25 M
sucrose, 20 mM Tris 20 mM pH 7.4, 1 mM EDTA, 1 mM
EGTA, 1:1000 Okadaic acid 100 ng/ml in ethanol, 1:1000
Calyculin A 100 ng/ml in ethanol, 1:100 Pierce phosphatase
inhibitor cocktail, protease inhibitor cocktail (Roche).
Supernatant and pellet (resuspended in homogenization
buffer in the same volume used for homogenization) was
used and protein concentration was determined from the
supernatant by Bradford (Bio-Rad). Thirty microgram
protein of the supernatant was loaded (LDS Sample Buffer,
Sample Reducing Agent, Invitrogen, heated for 10 min at
958C) on NuPAGE 4–12% Bis–tris gel 1.0 mM (Invitrogen)
and ran at 180 V for 40–50 min with NuPAGE MES SDS
Running Buffer (Invitrogen) or NuPAGE 3–8% Tris-Acetate
gel 1.0 mM ran at 150 V for 60 min with Tris-Acetate SDS
running buffer (Invitrogen). Gels were blotted by semi wet
transfer (Invitrogen × Cell II Blot Module) with NuPAGE
Transfer Buffer, 10% (for one gel) or 20% methanol (for
two gels) on polyvinylidene diﬂuoride transfer membrane
(Immobilon-P, Invitrogen) at constant 30 V for 1 h. For
Li-cor Odyssey detection, membrane was blocked for 1 h at
room temperature in Odyssey Blocking Buffer (Odyssey, 1:1
diluted with phosphate buffered saline (PBS)) and then incu-
bated with primary antibody in Odyssey Blocking Buffer
(diluted 1:1 with PBS, containing 0.1% or 0.05% Tween 20)
overnight at 48C. Primary antibodies used: mouse anti-b-actin
(Sigma, 1:50000); anti-LRRK2 MJJF2 c41 (Michael J. Fox
Foundation/Epitomics, 1:2500); mouse anti-a-synuclein (BD
Transduction, 1:5000); all subsequent antibodies were from
Cell Signaling (rabbit polyclonal, exceptions indicated) and
used at 1:1000: anti-S6 (rabbit monoclonal),
anti-P-S6(Ser235/236), anti-4E-BP1, anti-P-4E-BP1(Thr37/
46), anti-Akt, anti-P-Akt(S473), anti-TSC2, anti-LC3B and
anti-mTOR. Membranes were washed four times for 5 min
at room temperature in PBS containing 0.1% or 0.05%
Tween 20 and then incubated for 45 min (light protected)
with second antibodies [Alexa Fluor 680, F(ab′)2 fragment
of goat anti-mouse (Invitrogen); IRDye 800CW anti-rabbit
IgG (Li-cor); both 1:5000] in Odyssey Blocking Buffer
(diluted 1:1 in PBS, containing 0.1% or 0.05% Tween20).
Membranes were again washed four times for 5 min at room
temperature in PBS containing 0.1% or 0.05 Tween 20, then
washed two times for 5 min at room temperature in PBS
only and ﬁnally scanned on the Odyssey Li-cor System.
Kinase assay
The Bac-to-Bac Baculovirus Expression System (Invitrogen)
was used (according to the protocol of the manufacturer) to
express N-terminal HIS-GST-tagged (6×Histidine- and
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The LRRK2 constructs consisted of a part of LRRK2
(amino acids 1675–2527) which produced stable and
active LRRK2 protein (HIS-GST-hLRRK2 1675-2527
G2019S and HIS-GST-hLRRK2 1675-2527 D1994S). Cells
were harvested, centrifuged at 3000 rpm for 7 min and
HIS-GST-hLRRK2 1675-2527 G2019S and D1994S were
puriﬁed by GST SpinTrap columns (GE Healthcare Life
Sciences). Brieﬂy, the cell pellet was lysed in lysis buffer
(50 mM Tis–HCl, 150 mM NaCl, 2 mM DTT, 0.02% Tween
20, 0.5 mM EDTA, 20% glycerol, 1X complete (protease inhi-
bitors, Roche). Centrifugation, sonication and puriﬁcation
were performed according to the protocol of the manufacturer
(GE Healthcare Life Sciences). Lysate were applied to the
GST SpinTrap column, washed once with PBS, then three
times with washing buffer (20 mM Tris–HCl, 2 mM DTT,
0.1 mg/ml bovine serum albumin (BSA), 0.5 mM EDTA,
20% glycerol, 1 mM Na3VO4,5m M b-glycerophosphate) and
eluted with elution buffer (50 mM Tris–HCl, 0.1 mg/ml
BSA, 20% glycerol, 5 mM b-glycerophosphate, 10 mM GSH
(reduced glutathione, GE Healthcare Life Sciences). The
kinase reaction was performed by diluting the components to
3-fold ﬁnal concentration in 1× kinase buffer (50 mM
Hepes, 1 mM DTT, 0.6 mM EGTA, 10 mM MgCl2,3 m M
MnCl2): ATP to 750 mM (10 mM ATP stock; Biolabs), GST-
4xLRRKTide long [as a 4× repeat fused to GST, (58)] to
6m M, while GST SpinTrap elution fraction #1 was not
diluted. The ﬁnal reaction volume was 15 ml: 5 ml 3x ATP,
5 ml 3x GST-LRRKtide and 5 ml GST-hLRRK2 1675-2527
constructs. Reaction was incubated for 30 min at room tem-
perature, stopped by adding 5 ml 4xLDS sample buffer (Invi-
trogen, with 200 mM DTT) and heating to 908C for 10 min,
analyzed on western blot (4–12% Tris-Acetate gels and
semi-dry blotting, Invitrogen) using anti-LRRK2 CK (home-
made, directed against the c-terminus of the kinase domain
of LRRK2; rabbit, 1:500) and anti-phospho-ezrin (rabbit,
Cell Signaling Technology, 1:1000) antibodies and visualized
with Li-Cor Odyssey.
Histopathological analysis
Following necropsy, organs were ﬁxed in 4% neutral
phosphate-buffered formalin for 1 day, then transferred to
PBS, trimmed, embedded in parafﬁn wax, sectioned and
stained with hematoxylin and eosin (H&E) or left unstained
for autoﬂuorescence analysis. The tissue slices were evaluated
and reviewed by pathologists.
Immunohistochemistry
Antibodies/dilutions used for immunohistochemistry and im-
munoﬂuorescence staining:
primary antibodies: polyclonal rabbit anti-LAMP1 (Abcam
ab24210); monoclonal rat anti-LAMP2 (SouthernBiotech;
1:250); polyclonal rabbit anti-MUC1 (Mucin-1) (Abcam
ab15481); polyclonal rabbit anti-GFAP (DAKO #Z0334;
1:5000); polyclonal rabbit anti-Iba1 (WAKO chemicals,
#019-19471; 1:500); polyclonal rabbit anti-TH (Novus Biolo-
gicals NB300-109; 1:500); monoclonal rat anti-DAT (Chemi-
con MAB369; 1:200); monoclonal rabbit anti-DARPP-32
(Cell Signalling # 2306; 1:500); polyclonal rabbit
anti-a-synuclein (Chemicon AB 5038; 1:1000); monoclonal
mouse anti-a-synuclein (Abcam 4D6; 1:1000); polyclonal
guinea pig anti-p62 (C-terminus) (Progen, 1:100); monoclonal
mouse anti-neuroﬁlament (Covance SMI310R; 1:1000). Sec-
ondary antibodies: biotinylated goat anti-guinea pig (Vector-
labs, 1:200); biotinylated goat anti-mouse (Jackson
ImmunoResearch; 1:1000); biotinylated goat anti-rat
(Jackson ImmunoResearch; 1:1000); biotinylated goat anti-
rabbit (Jackson ImmunoResearch; 1:1000); Alexa488-labeled
goat anti-rat (Invitrogen, 1:500); Alexa488-labeled goat anti-
rabbit (Invitrogen; 1:500).
Automated immunohistochemistry. Mice were transcardially
perfused ﬁrst with PBS and then with 4% paraformaldehyde
in PBS. Brains and kidneys were prepared, postﬁxed for
another 2 days at 48C with 4% paraformaldehyde in PBS
and embedded in parafﬁn according to standard procedures.
Four micrometer para-sagittal parafﬁn sections were
mounted on SuperFrost Plus slides and automatically immu-
nostained using the Discovery XT technology (Ventana/
Roche diagnostics). Brieﬂy, sections were deparafﬁnized,
rehydrated, subjected to antigen retrieval by heating with
CC1 cell conditioning buffer (Ventana/Roche Diagnostics),
incubated for 60 min at room temperature with primary anti-
body diluted in antibody diluent (Ventana/Roche Diagnostics),
incubated with the respective biotinylated secondary antibody
diluted in Ventana antibody dilution, reacted with DABMab
kit (Ventana/Roche Diagnistics) and counterstained with
blueing reagent (Ventana/Roche Diagnostics). Digital slides
were generated with MIRAX (Zeiss) scanner technology.
Manual immunohistochemistry and immunﬂuorescence stain-
ing of DARPP-32, TH and DAT for quantitative image ana-
lysis. Parafﬁn sections were dewaxed, rehydrated, subjected
to antigen retrieval by microwaving the slides for 10 min at
988C in 0.1 M citrate buffer pH 6.0, incubated for 1 h at
room temperature in PBS containing 2% goat serum, reacted
over night at 48C with primary antibody diluted in PBS/2%
goat serum, stained with the appropriate Alexa488- or Biotin-
labeled secondary goat antibody diluted in PBS. For the
biotin-labeled secondary antibody ABC reagent (Vectorlabs)
for 1 h at room temperature was applied with subsequent
washes in PBS, developed with DAB stain, desalted in
0.01 M Tris (pH 7.8) and mounted with Eu-kitt.
Immunoﬂuorescence-stained slides were mounted with
ProLong antifade containing 4′,6-diamidino-2-phenylindole
(DAPI) (Invitrogen). Immunoﬂuorescence in the striatum
was imaged, at consistent exposure time for the respective
marker, with an Olympus BX51 microscope equipped with ap-
propriate ﬂuorescence ﬁlters and colorview III digital camera.
Fluorescence intensity in the striatum was analyzed with CellF
image analysis software (Soft Imaging Systems/Olympus).
Each six sagittal sections were analyzed per animal.
Electron microscopy
Kidneys and lungs were ﬁxed with 3% glutaraldehyde in 0.1 M
cacodylate buffer, pH 7.4, for about 1 h at 48C and 1% OsO4
in 0.1 M cacodylate buffer, pH 7.4, for 1 h at 48C. After post-
4220 Human Molecular Genetics, 2011, Vol. 20, No. 21ﬁxation, the tissues were dehydrated in graded acetone solu-
tions, and embedded in Epon. For microscopic evaluation,
semi-thin sections were prepared from tissue blocks, stained
with toluidine blue and examined with a Zeiss light micro-
scope. Based on these light microscopic investigations, ultra-
thin sections from selected tissue blocks were counterstained
with uranyl acetate and lead citrate and examined with a
Philips CM 10 transmission electron microscope.
Urinalysis
Urine samples were collected into plain tubes. Total protein
and creatinine were determined, using a Cobas 6000
w analyz-
er. Urine total protein concentration was analyzed with the
benzethonium chloride assay with a g-globulin recovery rate
which is 30% less than that of albumin.
Telemetric blood pressure and heart rate measurements
The radio-telemetry system (Data Sciences Int.) used in this
study is composed of four basic components: an implantable
transmitter (AM unit, model TLM-PAC10, volume: 1.1 cc,
weight: 1.4 g) which continuously senses and transmits infor-
mation from within the animal, one receiver located under the
home cage, a matrix interface for coordination of signals and a
computer-based data acquisition system for collection, ana-
lysis and storage of data. The body of the transmitter was
implanted s.c. in aseptic conditions into the ﬂank of the
animal under isoﬂurane anesthesia. The sensing catheter was
inserted into the left femoral artery. The total operation time
for the implantation of the telemetry transmitter was about
40 min. Postoperative analgesia was provided using Buprenor-
phin (Temgesic
w) injection of 0.05 mg/kg s.c. twice, immedi-
ately after surgery and 8–12 h later. Following surgery, the
unconscious animal is placed on soft material in a clean
cage with water ad libitum. The animals were allowed a
period of 2–3 weeks to recover from surgery before starting
acquisition of any physiological data. Mean, systolic and dia-
stolic blood pressure and heart rate were recorded continuous-
ly in all animals over 24 h up to 8 days, and analyzed in 1 min
cyclic runs for 10 s with a 500 Hz sampling rate.
Motility cages
Locomotor activity was measured with the TSE system
(process control type 302013-CD, software: Motilita ¨tsmess-
system 4.2) in motility cages (Makrolon Typ III with a lid
and without embedding). Cages were changed after each
animal. After the habituation phase (30–60 min), animals
were taken out of the cage, administered the drug and then
placed back into the cage and further monitored for motility
(30–60 min). The dopamine-receptor antagonist/agonists
SCH23390, haloperidol, quinpirole and SKF38393 (all from
Sigma) were administered s.c. in a physiological NaCl solu-
tion. D-amphetamine hemisulfate (Sigma) and cocaine-HCl
(Sigma) were administered i.p. (10 ml/kg) in a physiological
NaCl solution.
Animal maintenance and LRRK2 kinase inhibitor
drug administration
The animals were housed in a temperature-controlled room that
was maintained on a 12 h light/dark cycle. Food and water were
available ad libitum. Mice were administered orally with
30 mg/kg LRRK2 kinase inhibitor compound (dissolved in
0.5% methylcellulose with 0.5% Tween 80, administration
volume 10 ml/kg) twice daily (morning/afternoon) for 5 days
and were killed 2 h after last dosing. Novartis is willing to
provide said LRRK2 kinase inhibitor under a material transfer
agreement for academic research and non-commercial purposes.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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